NCT06286254 - Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection | Biotech Hunter

Enrollment

742

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

April 20, 2024

Study Completion Date

September 30, 2024

Conditions

Acute Respiratory Viral Infection

Interventions

DRUG

Cycloferone

Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.

Trial Locations (13)

Clinic Zvezdnaya, Saint Petersburg

Medical center Astarta, Saint Petersburg

Medical Center Energiya Zdoroviy, Saint Petersburg

Medical Center Meily, Saint Petersburg

Medical Center Oris, Saint Petersburg

Medical Center PiterClinica, Saint Petersburg

Medical Center Reavita Med, Saint Petersburg

Medical Center SOGAZ, Saint Petersburg

Research Center Eco-Safety, Saint Petersburg

Сity clinic No. 117, Saint Petersburg

Сity clinic No. 44, Saint Petersburg

Сity clinic No.109, Saint Petersburg

Сity hospital No. 40, Sestroretsk

All Listed Sponsors

lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY